Image-derived biomarkers and multimodal imaging strategies for lung cancer management

详细信息    查看全文

• 作者：Alexander W. Sauter (1) (2)
  Nina Schwenzer (1)
  Mathew R. Divine (2)
  Bernd J. Pichler (2)
  Christina Pfannenberg (1)
  
  1. Diagnostic and Interventional Radiology ; Department of Radiology ; Eberhard Karls University Tuebingen ; Hoppe-Seyler-Str. 3 ; 72076 ; Tuebingen ; Germany
  2. Werner Siemens Imaging Center ; Department of Preclinical Imaging and Radiopharmacy ; Eberhard Karls University Tuebingen ; 72076 ; Tuebingen ; Germany
  
• 关键词：Lung cancer ; Non ; small ; cell lung cancer ; NSCLC ; FDG PET/CT ; CT perfusion ; VPCT ; Hybrid imaging ; MRI ; PET/MRI
• 刊名：European Journal of Nuclear Medicine and Molecular Imaging
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：42
• 期：4
• 页码：634-643
• 全文大小：3,046 KB
• 参考文献：1. Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D (2011) Global cancer statistics. CA Cancer J Clin 61: pp. 69-90 22/caac.20107" target="_blank" title="It opens in new window">CrossRef
  2. Devesa, SS, Bray, F, Vizcaino, AP, Parkin, DM (2005) International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117: pp. 294-299 2/ijc.21183" target="_blank" title="It opens in new window">CrossRef
  3. Morgensztern, D, Ng, SH, Gao, F, Govindan, R (2010) Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5: pp. 29-33 20c" target="_blank" title="It opens in new window">CrossRef
  4. Silvestri, GA, Gonzalez, AV, Jantz, MA, Margolis, ML, Gould, MK, Tanoue, LT (2013) Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143: pp. e211S-e2150 2-2355" target="_blank" title="It opens in new window">CrossRef
  5. Akin, O, Brennan, SB, Dershaw, DD, Ginsberg, MS, Gollub, MJ, Sch枚der, H (2012) Advances in oncologic imaging: update on 5 common cancers. CA Cancer J Clin 62: pp. 364-393 22/caac.21156" target="_blank" title="It opens in new window">CrossRef
  6. Reck, M, Heigener, DF, Mok, T, Soria, JC, Rabe, KF (2013) Management of non-small-cell lung cancer: recent developments. Lancet 382: pp. 709-719 2-0" target="_blank" title="It opens in new window">CrossRef
  7. Sandler, A, Gray, R, Perry, MC, Brahmer, J, Schiller, JH, Dowlati, A (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: pp. 2542-2550 CrossRef
  8. Scagliotti, GV, Parikh, P, Pawel, J, Biesma, B, Vansteenkiste, J, Manegold, C (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: pp. 3543-3551 200/JCO.2007.15.0375" target="_blank" title="It opens in new window">CrossRef
  9. Pignon, JP, Tribodet, H, Scagliotti, GV, Douillard, JY, Shepherd, FA, Stephens, RJ (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 26: pp. 3552-3559 200/JCO.2007.13.9030" target="_blank" title="It opens in new window">CrossRef
  10. Sause, W, Kolesar, P, Taylor, S, Johnson, D, Livingston, R, Komaki, R (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: pp. 358-364 2.358" target="_blank" title="It opens in new window">CrossRef
  11. Rosell, R, Carcereny, E, Gervais, R, Vergnenegre, A, Massuti, B, Felip, E (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: pp. 239-246 2045(11)70393-X" target="_blank" title="It opens in new window">CrossRef
  12. Seo, JS, Ju, YS, Lee, WC, Shin, JY, Lee, JK, Bleazard, T (2012) The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22: pp. 2109-2119 2" target="_blank" title="It opens in new window">CrossRef
  13. Annema, JT, Meerbeeck, JP, Rintoul, RC, Dooms, C, Deschepper, E, Dekkers, OM (2010) Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA 304: pp. 2245-2252 2010.1705" target="_blank" title="It opens in new window">CrossRef
  14. Fischer, B, Lassen, U, Mortensen, J, Larsen, S, Loft, A, Bertelsen, A (2009) Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 361: pp. 32-39 CrossRef
  15. Zeliadt, SB, Loggers, ET, Slatore, CG, Au, DH, Hebert, PL, Klein, GJ (2014) Preoperative PET and the reduction of unnecessary surgery among newly diagnosed lung cancer patients in a community setting. J Nucl Med 55: pp. 379-385 2967/jnumed.113.124230" target="_blank" title="It opens in new window">CrossRef
  16. Rami-Porta, R, Crowley, JJ, Goldstraw, P (2009) The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15: pp. 4-9
  17. Humphrey, LL, Deffebach, M, Pappas, M, Baumann, C, Artis, K, Mitchell, JP (2013) Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med 159: pp. 411-420 26/0003-4819-159-6-201309170-00690" target="_blank" title="It opens in new window">CrossRef
  18. Walker, CM, Chung, JH, Abbott, GF, Little, BP, El-Sherief, AH, Shepard, JA (2012) Mediastinal lymph node staging: from noninvasive to surgical. AJR Am J Roentgenol 199: pp. W54-W64 2214/AJR.11.7446" target="_blank" title="It opens in new window">CrossRef
  19. Gould, MK, Kuschner, WG, Rydzak, CE, Maclean, CC, Demas, AN, Shigemitsu, H (2003) Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 139: pp. 879-892 26/0003-4819-139-11-200311180-00013" target="_blank" title="It opens in new window">CrossRef
  20. Lardinois, D, Weder, W, Hany, TF, Kamel, EM, Korom, S, Seifert, B (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348: pp. 2500-2507 22136" target="_blank" title="It opens in new window">CrossRef
  21. Rosado-de-Christenson, ML, Templeton, PA, Moran, CA (1994) Bronchogenic carcinoma: radiologic-pathologic correlation. Radiographics 14: pp. 429-446 2.8190965" target="_blank" title="It opens in new window">CrossRef
  22. Sun, JS, Park, KJ, Sheen, SS, Yoon, JK, Yoon, SN, Lee, KB (2009) Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers. Lung Cancer 66: pp. 205-210 2009.01.009" target="_blank" title="It opens in new window">CrossRef
  23. Goeckenjan, G, Sitter, H, Thomas, M, Branscheid, D, Flentje, M, Griesinger, F (2011) Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 65: pp. 39-59 255961" target="_blank" title="It opens in new window">CrossRef
  24. Silvestri, GA, Gould, MK, Margolis, ML, Tanoue, LT, McCrory, D, Toloza, E (2007) Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 132: pp. 178S-201 CrossRef
  25. Rintoul, RC, Tournoy, KG, Daly, H, Carroll, NR, Buttery, RC, Kralingen, K (2009) EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes 鈥?an international multi-centre experience. J Thorac Oncol 4: pp. 44-48 CrossRef
  26. Geus-Oei, LF, Heijden, HF, Corstens, FH, Oyen, WJ (2007) Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 110: pp. 1654-1664 2/cncr.22979" target="_blank" title="It opens in new window">CrossRef
  27. Paesmans, M, Berghmans, T, Dusart, M, Garcia, C, Hossein-Foucher, C, Lafitte, JJ (2010) Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 5: pp. 612-619
  28. Berghmans, T, Paesmans, M, Sculier, JP (2011) Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol 3: pp. 127-138 CrossRef
  29. Machtay, M, Duan, F, Siegel, BA, Snyder, BS, Gorelick, JJ, Reddin, JS (2013) Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol 31: pp. 3823-3830 200/JCO.2012.47.5947" target="_blank" title="It opens in new window">CrossRef
  30. Usmanij, EA, Geus-Oei, LF, Troost, EG, Peters-Bax, L, Heijden, EH, Kaanders, JH (2013) 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med 54: pp. 1528-1534 2967/jnumed.112.116921" target="_blank" title="It opens in new window">CrossRef
  31. Takahashi, R, Hirata, H, Tachibana, I, Shimosegawa, E, Inoue, A, Nagatomo, I (2012) Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res 18: pp. 220-228 2.CCR-11-0868" target="_blank" title="It opens in new window">CrossRef
  32. Tiseo, M, Ippolito, M, Scarlattei, M, Spadaro, P, Cosentino, S, Latteri, F (2014) Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. Cancer Chemother Pharmacol 73: pp. 299-307 280-013-2356-x" target="_blank" title="It opens in new window">CrossRef
  33. Schaake, EE, Kappers, I, Codrington, HE, Vald茅s Olmos, RA, Teertstra, HJ, Pel, R (2012) Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol 30: pp. 2731-2738 200/JCO.2011.39.4882" target="_blank" title="It opens in new window">CrossRef
  34. Ulger, S, Demirci, NY, Eroglu, FN, Cengiz, HH, Tunc, M, Tatci, E (2014) High FDG uptake predicts poorer survival in locally advanced nonsmall cell lung cancer patients undergoing curative radiotherapy, independently of tumor size. J Cancer Res Clin Oncol 140: pp. 495-502 2-014-1591-9" target="_blank" title="It opens in new window">CrossRef
  35. Vera, P, Mezzani-Saillard, S, Edet-Sanson, A, M茅nard, JF, Modzelewski, R, Thureau, S (2014) FDG PET during radiochemotherapy is predictive of outcome at 1聽year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2). Eur J Nucl Med Mol Imaging 41: pp. 1057-1065 259-014-2687-9" target="_blank" title="It opens in new window">CrossRef
  36. Nair, VS, Gevaert, O, Davidzon, G, Napel, S, Graves, EE, Hoang, CD (2012) Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res 72: pp. 3725-3734 2.CAN-11-3943" target="_blank" title="It opens in new window">CrossRef
  37. Kaira, K, Serizawa, M, Koh, Y, Takahashi, T, Yamaguchi, A, Hanaoka, H (2014) Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer 83: pp. 197-204 2013.11.025" target="_blank" title="It opens in new window">CrossRef
  38. Vesselle, H, Salskov, A, Turcotte, E, Wiens, L, Schmidt, R, Jordan, CD (2008) Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 3: pp. 971-978 CrossRef
  39. Suzawa, N, Ito, M, Qiao, S, Uchida, K, Takao, M, Yamada, T (2011) Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size. Lung Cancer 72: pp. 191-198 2010.08.017" target="_blank" title="It opens in new window">CrossRef
  40. Lasnon, C, Desmonts, C, Quak, E, Gervais, R, Do, P, Dubos-Arvis, C (2013) Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging 40: pp. 985-996 259-013-2391-1" target="_blank" title="It opens in new window">CrossRef
  41. Vach, W, H酶ilund-Carlsen, PF, Gerke, O, Weber, WA (2011) Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. J Nucl Med 52: pp. 77S-85 2967/jnumed.110.085704" target="_blank" title="It opens in new window">CrossRef
  42. Takahara, T, Imai, Y, Yamashita, T, Yasuda, S, Nasu, S, Cauteren, M (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22: pp. 275-282
  43. Chen, L, Zhang, J, Bao, J, Zhang, L, Hu, X, Xia, Y (2013) Meta-analysis of diffusion-weighted MRI in the differential diagnosis of lung lesions. J Magn Reson Imaging 37: pp. 1351-1358 2/jmri.23939" target="_blank" title="It opens in new window">CrossRef
  44. Koyama, H, Ohno, Y, Nishio, M, Takenaka, D, Yoshikawa, T, Matsumoto, S (2014) Diffusion-weighted imaging vs STIR turbo SE imaging: capability for quantitative differentiation of small-cell lung cancer from non-small-cell lung cancer. Br J Radiol 87: pp. 20130307 259/bjr.20130307" target="_blank" title="It opens in new window">CrossRef
  45. Zhai, G, Kim, H, Sarver, D, Samuel, S, Whitworth, L, Umphrey, H (2014) Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy. J Magn Reson Imaging 39: pp. 1588-1594 2/jmri.24319" target="_blank" title="It opens in new window">CrossRef
  46. Schraml, C, Schwenzer, NF, Martirosian, P, Bitzer, M, Lauer, U, Claussen, CD (2009) Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 193: pp. W301-W307 2214/AJR.08.2289" target="_blank" title="It opens in new window">CrossRef
  47. Evelhoch, JL (1999) Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10: pp. 254-259 2/(SICI)1522-2586(199909)10:3<254::AID-JMRI5>3.0.CO;2-9" target="_blank" title="It opens in new window">CrossRef
  48. Sourbron, SP, Buckley, DL (2013) Classic models for dynamic contrast-enhanced MRI. NMR Biomed 26: pp. 1004-1027 2/nbm.2940" target="_blank" title="It opens in new window">CrossRef
  49. Chang, YC, Yu, CJ, Chen, CM, Hu, FC, Hsu, HH, Tseng, WY (2012) Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging 36: pp. 387-396 2/jmri.23660" target="_blank" title="It opens in new window">CrossRef
  50. Hoekstra, CJ, Stroobants, SG, Hoekstra, OS, Smit, EF, Vansteenkiste, JF, Lammertsma, AA (2002) Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res 8: pp. 2109-2115
  51. Kramer, GM, Yaqub, M, Bahce, I, Smit, EF, Lubberink, M, Hoekstra, OS (2013) CT-perfusion versus [(15)O]H2O PET in lung tumors: effects of CT-perfusion methodology. Med Phys 40: pp. 052502 CrossRef
  52. Miles, KA, Charnsangavej, C, Lee, FT, Fishman, EK, Horton, K, Lee, TY (2000) Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 7: pp. 840-850 2(00)80632-7" target="_blank" title="It opens in new window">CrossRef
  53. Haberland, U, Klotz, E, Abolmaali, N (2010) Performance assessment of dynamic spiral scan modes with variable pitch for quantitative perfusion computed tomography. Investig Radiol 45: pp. 378-386
  54. Ma, SH, Le, HB, Jia, BH, Wang, ZX, Xiao, ZW, Cheng, XL (2008) Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer 8: pp. 186 2407-8-186" target="_blank" title="It opens in new window">CrossRef
  55. Spira, D, Neumeister, H, Spira, SM, Hetzel, J, Spengler, W, Weyhern, CH (2013) Assessment of tumor vascularity in lung cancer using volume perfusion CT (VPCT) with histopathologic comparison: a further step toward an individualized tumor characterization. J Comput Assist Tomogr 37: pp. 15-21 277c84f" target="_blank" title="It opens in new window">CrossRef
  56. Tacelli, N, Santangelo, T, Scherpereel, A, Duhamel, A, Deken, V, Klotz, E (2013) Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. Eur Radiol 23: pp. 2127-2136 2821-2" target="_blank" title="It opens in new window">CrossRef
  57. Wang, J, Wu, N, Cham, MD, Song, Y (2009) Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 193: pp. 1090-1096 2214/AJR.08.1367" target="_blank" title="It opens in new window">CrossRef
  58. Sauter, AW, Wehrl, HF, Kolb, A, Judenhofer, MS, Pichler, BJ (2010) Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med 16: pp. 508-515 2010.08.003" target="_blank" title="It opens in new window">CrossRef
  59. Hanahan, D, Weinberg, RA (2011) Hallmarks of cancer: the next generation. Cell 144: pp. 646-674 2011.02.013" target="_blank" title="It opens in new window">CrossRef
  60. Holland, JP, Cumming, P, Vasdev, N (2012) PET of signal transduction pathways in cancer. J Nucl Med 53: pp. 1333-1336 2967/jnumed.112.105387" target="_blank" title="It opens in new window">CrossRef
  61. Wood, SL, Pernemalm, M, Crosbie, PA, Whetton, AD (2014) The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev 40: pp. 558-566 2013.10.001" target="_blank" title="It opens in new window">CrossRef
  62. Nygaard, AD, Holdgaard, PC, Spindler, KL, Pallisgaard, N, Jakobsen, A (2014) The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br J Cancer 110: pp. 363-368 2013.705" target="_blank" title="It opens in new window">CrossRef
  63. Lam, S, Boyle, P, Healey, GF, Maddison, P, Peek, L, Murray, A (2011) EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila) 4: pp. 1126-1134 207.CAPR-10-0328" target="_blank" title="It opens in new window">CrossRef
  64. Trigonis, I, Koh, PK, Taylor, B, Tamal, M, Ryder, D, Earl, M (2014) Early reduction in tumour [(18)F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. Eur J Nucl Med Mol Imaging 41: pp. 682-693 259-013-2632-3" target="_blank" title="It opens in new window">CrossRef
  65. Kahraman, D, Scheffler, M, Zander, T, Nogova, L, Lammertsma, AA, Boellaard, R (2011) Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3鈥?deoxy-3鈥?18F-fluorothymidine PET. J Nucl Med 52: pp. 1871-1877 2967/jnumed.111.094458" target="_blank" title="It opens in new window">CrossRef
  66. Zander, T, Scheffler, M, Nogova, L, Kobe, C, Engel-Riedel, W, Hellmich, M (2011) Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 29: pp. 1701-1708 200/JCO.2010.32.4939" target="_blank" title="It opens in new window">CrossRef
  67. Lee, SJ, Yeo, JS, Lee, HJ, Lee, EJ, Kim, SY, Jang, SJ (2014) Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 41: pp. 1327-1335 259-014-2712-z" target="_blank" title="It opens in new window">CrossRef
  68. Putora, PM, M眉ller, J, Borovicka, J, Plasswilm, L, Schmidt, F (2013) Relevance of incidental colorectal FDG-PET/CT-enhanced lesions. Onkologie 36: pp. 200-204 2" target="_blank" title="It opens in new window">CrossRef
  69. Mishani, E, Hagooly, A (2009) Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer. J Nucl Med 50: pp. 1199-1202 2967/jnumed.109.062117" target="_blank" title="It opens in new window">CrossRef
  70. Miao, Z, Ren, G, Liu, H, Qi, S, Wu, S, Cheng, Z (2012) PET of EGFR expression with an 18F-labeled affibody molecule. J Nucl Med 53: pp. 1110-1118 2967/jnumed.111.100842" target="_blank" title="It opens in new window">CrossRef
  71. Memon, AA, Jakobsen, S, Dagnaes-Hansen, F, Sorensen, BS, Keiding, S, Nexo, E (2009) Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 69: pp. 873-878 2.CAN-08-3118" target="_blank" title="It opens in new window">CrossRef
  72. Yeh, HH, Ogawa, K, Balatoni, J, Mukhapadhyay, U, Pal, A, Gonzalez-Lepera, C (2011) Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A 108: pp. 1603-1608 CrossRef
  73. Pecking, AP, Bellet, D, Alberini, JL (2012) Immuno-SPET/CT and immuno-PET/CT: a step ahead to translational imaging. Clin Exp Metastasis 29: pp. 847-852 2-9501-5" target="_blank" title="It opens in new window">CrossRef
  74. Staudacher, AH, Al-Ejeh, F, Fraser, CK, Darby, JM, Roder, DM, Ruszkiewicz, A (2014) The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB庐. EJNMMI Res 4: pp. 2 2191-219X-4-2" target="_blank" title="It opens in new window">CrossRef
  75. Tartour, E, Zitvogel, L (2013) Lung cancer: potential targets for immunotherapy. Lancet Respir Med 1: pp. 551-563 2213-2600(13)70159-0" target="_blank" title="It opens in new window">CrossRef
  76. Hodi, FS, O鈥橠ay, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: pp. 711-723 CrossRef
  77. Neumann, A, H枚rzer, H, Hillen, N, Klingel, K, Schmid-Horch, B, B眉hring, HJ (2013) Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer. Cancer Immunol Immunother 62: pp. 1485-1497 262-013-1454-2" target="_blank" title="It opens in new window">CrossRef
  78. H枚ckel, M, Vaupel, P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: pp. 266-276 266" target="_blank" title="It opens in new window">CrossRef
  79. Beer, AJ, Lorenzen, S, Metz, S, Herrmann, K, Watzlowik, P, Wester, HJ (2008) Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med 49: pp. 22-29 2967/jnumed.107.045864" target="_blank" title="It opens in new window">CrossRef
  80. Graves, EE, Maity, A, Le, QT (2010) The tumor microenvironment in non-small-cell lung cancer. Semin Radiat Oncol 20: pp. 156-163 2010.01.003" target="_blank" title="It opens in new window">CrossRef
  81. Bollineni, VR, Wiegman, EM, Pruim, J, Groen, HJ, Langendijk, JA (2012) Hypoxia imaging using positron emission tomography in non-small cell lung cancer: implications for radiotherapy. Cancer Treat Rev 38: pp. 1027-1032 2012.04.003" target="_blank" title="It opens in new window">CrossRef
  82. Thorwarth, D, Alber, M (2010) Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol 97: pp. 172-175 2010.05.012" target="_blank" title="It opens in new window">CrossRef
  83. Baek, S, Choi, CM, Ahn, SH, Lee, JW, Gong, G, Ryu, JS (2012) Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res 18: pp. 5427-5437 2.CCR-12-0214" target="_blank" title="It opens in new window">CrossRef
  84. Kaira, K, Oriuchi, N, Shimizu, K, Imai, H, Tominaga, H, Yanagitani, N (2010) Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-伪-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol 37: pp. 911-916 2010.06.004" target="_blank" title="It opens in new window">CrossRef
  85. Kaira, K, Oriuchi, N, Shimizu, K, Tominaga, H, Yanagitani, N, Sunaga, N (2009) 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med 50: pp. 1770-1776 2967/jnumed.109.066837" target="_blank" title="It opens in new window">CrossRef
  86. Ippolito, D, Capraro, C, Guerra, L, Ponti, E, Messa, C, Sironi, S (2013) Feasibility of perfusion CT technique integrated into conventional 18FDG/PET-CT studies in lung cancer patients: clinical staging and functional information in a single study. Eur J Nucl Med Mol Imaging 40: pp. 156-165 259-012-2273-y" target="_blank" title="It opens in new window">CrossRef
  87. Sauter, AW, Winterstein, S, Spira, D, Hetzel, J, Schulze, M, Mueller, M (2012) Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT. J Nucl Med 53: pp. 521-529 2967/jnumed.111.097865" target="_blank" title="It opens in new window">CrossRef
  88. Mankoff, DA, Dunnwald, LK, Partridge, SC, Specht, JM (2009) Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res 15: pp. 5294-5296 2.CCR-09-1448" target="_blank" title="It opens in new window">CrossRef
  89. Miles, KA, Griffiths, MR, Keith, CJ (2006) Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 33: pp. 22-28 259-005-1932-7" target="_blank" title="It opens in new window">CrossRef
  90. Sauter, AW, Spira, D, Schulze, M, Pfannenberg, C, Hetzel, J, Reimold, M (2013) Correlation between [18F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 40: pp. 677-684 259-012-2318-2" target="_blank" title="It opens in new window">CrossRef
  91. Elmpt, W, Das, M, H眉llner, M, Sharifi, H, Zegers, CM, Reymen, B (2013) Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer. Radiother Oncol 109: pp. 65-70 2013.08.032" target="_blank" title="It opens in new window">CrossRef
  92. Wehrl, HF, Sauter, AW, Judenhofer, MS, Pichler, BJ (2010) Combined PET/MR imaging 鈥?technology and applications. Technol Cancer Res Treat 9: pp. 5-20 2" target="_blank" title="It opens in new window">CrossRef
  93. Schwenzer, NF, Schraml, C, M眉ller, M, Brendle, C, Sauter, A, Spengler, W (2012) Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging 鈥?pilot study. Radiology 264: pp. 551-558 2111942" target="_blank" title="It opens in new window">CrossRef
  94. Schmidt, H, Brendle, C, Schraml, C, Martirosian, P, Bezrukov, I, Hetzel, J (2013) Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system. Investig Radiol 48: pp. 247-255 28d56a1" target="_blank" title="It opens in new window">CrossRef
  95. Ohno, Y, Koyama, H, Yoshikawa, T, Matsumoto, K, Takahashi, M, Cauteren, M (2011) T2* measurements of 3-T MRI with ultrashort TEs: capabilities of pulmonary function assessment and clinical stage classification in smokers. AJR Am J Roentgenol 197: pp. W279-W285 2214/AJR.10.5350" target="_blank" title="It opens in new window">CrossRef
  96. Gevaert, O, Xu, J, Hoang, CD, Leung, AN, Xu, Y, Quon, A (2012) Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data 鈥?methods and preliminary results. Radiology 264: pp. 387-396 2111607" target="_blank" title="It opens in new window">CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Nuclear Medicine
  Imaging and Radiology
  Orthopedics
  Cardiology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1619-7089

文摘

Non-small-cell lung cancer is the most common type of lung cancer and one of the leading causes of cancer-related death worldwide. For this reason, advances in diagnosis and treatment are urgently needed. With the introduction of new, highly innovative hybrid imaging technologies such as PET/CT, staging and therapy response monitoring in lung cancer patients have substantially evolved. In this review, we discuss the role of FDG PET/CT in the management of lung cancer patients and the importance of new emerging imaging technologies and radiotracer developments on the path to personalized medicine.